Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... 
Via Talk Markets
Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
HUTCHMED (China) Limited's (NASDAQ: ​HCM) pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints... 
Via Benzinga
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers Save Foods, Inc. (NASDAQ: SVFD) shares surged 76.6% to $1.13 in pre-market trading after gaining 15% on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! 
Via InvestorPlace
Sohu.com, Cloudflare And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. HUTCHMED (China) Limited (NYSE: HCM) shares dipped 14.1% to... 
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC)... 
Via Benzinga
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee 
From HUTCHMED (China) Limited
Via GlobeNewswire
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
10 Stocks Reacting To April PCE: Marvell Technology Leads The Rally
Via Benzinga
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.